| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-15-1338 |
| P698 | PubMed publication ID | 26423795 |
| P2093 | author name string | Roger B Cohen | |
| Geoffrey I Shapiro | |||
| Glen J Weiss | |||
| Devalingam Mahalingam | |||
| Bruce J Dezube | |||
| Jeffrey W Clark | |||
| John Sarantopoulos | |||
| Allison J Berger | |||
| R Donald Harvey | |||
| Hélène M Faessel | |||
| James M Cleary | |||
| John S Kauh | |||
| George Mulligan | |||
| Michael D Pickard | |||
| Kristine Burke | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 847-857 | |
| P577 | publication date | 2015-09-30 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors | |
| P478 | volume | 22 |
| Q34521260 | A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma |
| Q89719532 | ABCG2 Overexpression Contributes to Pevonedistat Resistance |
| Q96304533 | Anticancer drug discovery by targeting cullin neddylation |
| Q90284585 | Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment |
| Q54942210 | Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy. |
| Q53316010 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. |
| Q45931257 | Cullin E3 Ligase Activity Is Required for Myoblast Differentiation. |
| Q40303257 | Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction. |
| Q89402892 | DEPTOR modulates activation responses in CD4+ T cells and enhances immunoregulation following transplantation |
| Q28818350 | Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity |
| Q92198956 | Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours |
| Q34543264 | Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer |
| Q42292376 | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| Q64079078 | Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation |
| Q90130278 | Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes |
| Q50099283 | High-Content Monitoring of Drug Effects in a 3D Spheroid Model |
| Q51138159 | Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. |
| Q37737112 | Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. |
| Q64077463 | Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib |
| Q49720502 | Inhibition of neddylation pathway represses influenza virus replication and pro-inflammatory responses |
| Q48517497 | MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells |
| Q40648639 | Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment |
| Q100958600 | Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1 |
| Q49456490 | Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin |
| Q37150065 | Neddylation requires glycyl-tRNA synthetase to protect activated E2. |
| Q64081261 | Neddylation: a novel modulator of the tumor microenvironment |
| Q90173571 | Overexpression of Cullin4A correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma |
| Q90755927 | Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus |
| Q48216923 | Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML. |
| Q64981692 | Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. |
| Q92245139 | Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies |
| Q89984846 | Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy |
| Q93053120 | Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer |
| Q47692259 | Prospect of divergent roles for the CUL3 system in vascular endothelial cell function and angiogenesis |
| Q89598452 | Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease |
| Q47161331 | Proteasome-associated deubiquitinases and cancer |
| Q48538797 | Protein neddylation and its alterations in human cancers for targeted therapy |
| Q89936454 | Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer |
| Q92578250 | Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors |
| Q47095447 | Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides |
| Q90244662 | Rb and p53-deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival |
| Q92724115 | Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases |
| Q41991525 | Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication. |
| Q55270698 | Targeting CAND1 promotes caspase-8/RIP1-dependent apoptosis in liver cancer cells. |
| Q37634102 | Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. |
| Q57169761 | Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma |
| Q38736706 | Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). |
| Q92577230 | The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death |
| Q57809721 | The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma |
| Q52722174 | The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma. |
| Q61136484 | The replication initiation determinant protein (RepID) modulates replication by recruiting CUL4 to chromatin |
| Q89768702 | Ubiquitin and ubiquitin-like molecules in DNA double strand break repair |
| Q92823166 | Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer |
Search more.